Givat Shmuel, Israel – June 16, 2009 – Cimatron Limited (Nasdaq: CIMT), a leading provider of integrated CAD/CAM solutions for mold, tool and die makers as well as manufacturers of discrete parts, today announced that its latest release of CimatronE, Version 9, will be demonstrated at the 2009 NPE/MoldMaking Expo. The exhibition will take place June 22–26, 2009 at the McCormick Place Convention Center in Chicago, IL.

Helping tool makers and manufacturers deliver higher quality tools and products at lower costs and shorter cycle times, the CimatronE CAD/CAM solution suite addresses the entire process from quoting through design, engineering changes, NC, and EDM programming to delivery.

Highlights of the new and enhanced capabilities in CimatronE 9.0 include:

  • Greater mold design automation
  • A new application for defining electrode measuring points and probe path
  • New machining strategies for High Speed Machining (HSM) and 5-Axis milling
  • New capabilities for handling Product Manufacturing Information (PMI) throughout the design and manufacturing process
  • A new application for transfer die design
  • A new die quote generator

"We are proud to present the latest enhancements to the CimatronE product line at the NPE/MoldMaking Expo," said Bill Gibbs, President of Cimatron Technologies Inc. and Gibbs and Associates. "Cimatron is dedicated to providing the industry with the tools needed to increase efficiency and do more with less. Our integrated solution suite provides mold, tool and die makers with a unique opportunity to get ahead despite the sluggish economy."

The CimatronE solutions will be presented at booth #W103009, June 22–26, 2009 at the McCormick Place in Chicago, IL. For information and registration, visit

About Cimatron

With over 25 years of experience and more than 40,000 installations worldwide, Cimatron is a leading provider of integrated, CAD/CAM solutions for mold, tool and die makers as well as manufacturers of discrete parts. Cimatron is committed to providing comprehensive, cost-effective solutions that streamline manufacturing cycles, enable collaboration with outside vendors, and ultimately shorten product delivery time.

The Cimatron product line includes the CimatronE and GibbsCAM brands with solutions for mold design, die design, electrodes design, 2.5 to 5 axes milling, wire EDM, turn, mill-turn, rotary milling, multi-task machining, and tombstone machining. Cimatron's subsidiaries and extensive distribution network serve and support customers in the automotive, aerospace, medical, consumer plastics, electronics, and other industries in over 40 countries worldwide.

Cimatron is publicly traded on the NASDAQ exchange under the symbol CIMT. For more information, please visit the company web site at:

This press release includes forward looking statements, within the meaning of the Private Securities Litigation Reform Act Of 1995, which are subject to risk and uncertainties that could cause actual results to differ materially from those anticipated. Such statements may relate to the company's plans, objectives and expected financial and operating results. The words "may," "could," "would," "will," "believe," "anticipate," "estimate," "expect," "intend," "plan," and similar expressions or variations thereof are intended to identify forward-looking statements. Investors are cautioned that any such forward-looking statements are not guarantees of the future performance and involve risks and uncertainties, many of which are beyond the company's ability to control. The risks and uncertainties that may affect forward looking statements include, but are not limited to: currency fluctuations, global economic and political conditions, marketing demand for Cimatron products and services, long sales cycle, new product development, assimilating future acquisitions, maintaining relationships with customers and partners, and increased competition. For more details about the risks and uncertainties of the business, refer to the Company's filings with the Securities and Exchanges Commission. The company cannot assess the impact of or the extent to which any single factor or risk, or combination of them, may cause. Cimatron undertakes no obligation to publicly update or revise any forward looking statements, whether as a result of new information, future events or otherwise.